Abstract 258P
Background
Ovarian cancer leaves a detrimental effect on sexual health due to treatment modalities, hormonal imbalance, inability to accept body image after treatment related deformity and other psychological reasons. As the proportion of ovarian cancer survivors is increasing, it is very important to address the issue of sexual health in these patients, an issue which is generally unaddressed. The aim of our study was to asses sexual health in patients treated for ovarian cancer who were disease free at the time of analysis.
Methods
This single institute prospective study was conducted from April 2017 to November 2017. During the routine follow up visit to the hospital, patients who were disease free were recruited in the study. European Organisation of Research and Treatment for Cancer (EORTC) QLQ-OV 28 questionnaire was used to assess the sexual health. The impact of various factors on quality of life (QOL) scores was analysed using one-way analysis of variance (Univariate ANOVA). A p value of < 0.05 was considered as statistically significant.
Results
A total of 84 ovarian cancer patients were recruited. Median age at presentation was 45 years. All patients were clinically and biochemically disease free at the time of analysis. Seventy-two patients were married whereas 12 women were either unmarried or divorced or widows. Out of these 72 women, only 34 (47%) women were found to have had sex in last 3 months. A median score of 33.3 (22.2-66.6) was recorded for sexual function in QLQ-OV 28 questionnaire which was lesser than other domains of functional scale. The sexual score was significantly affected by presence of co-morbidities (p < 0.007), higher number of chemotherapy cycles (p < 0.001), fear of recurrence (p < 0.02), vaginal dryness and pain (p < 0.04).
Conclusions
Sexual health is a fundamental quality of life domain which is often compromised and underestimated in ovarian cancer patients. The present study showed that diagnosis and treatment of ovarian cancer has a negative impact on sexual health. As the proportion of ovarian cancer survivors continuously rising, there is a need to acknowledge and address the impact of treatment on sexual health.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract